These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 12735235

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Licofelone (Merckle).
    Ding C, Cicuttini F.
    IDrugs; 2003 Aug; 6(8):802-8. PubMed ID: 12917777
    [Abstract] [Full Text] [Related]

  • 10. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy.
    Dou QP, Smith DM, Daniel KG, Kazi A.
    Prog Cell Cycle Res; 2003 Aug; 5():441-6. PubMed ID: 14593738
    [Abstract] [Full Text] [Related]

  • 11. Bortezomib and its role in the management of patients with multiple myeloma.
    Orlowski RZ.
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
    [Abstract] [Full Text] [Related]

  • 12. Discovery of the ubiquitin proteasome system and its involvement in apoptosis.
    Melino G.
    Cell Death Differ; 2005 Sep; 12(9):1155-7. PubMed ID: 16094390
    [No Abstract] [Full Text] [Related]

  • 13. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy.
    Abu-Baker A, Messaed C, Laganiere J, Gaspar C, Brais B, Rouleau GA.
    Hum Mol Genet; 2003 Oct 15; 12(20):2609-23. PubMed ID: 12944420
    [Abstract] [Full Text] [Related]

  • 14. [Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma].
    Mikala G, Jákó J, Vályi-Nagy I.
    Orv Hetil; 2004 Jan 11; 145(2):67-74. PubMed ID: 14978877
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Assays for proteasome inhibition.
    Elliott PJ, Soucy TA, Pien CS, Adams J, Lightcap ES.
    Methods Mol Med; 2003 Jan 11; 85():163-72. PubMed ID: 12710207
    [No Abstract] [Full Text] [Related]

  • 17. Pralnacasan (vertex pharmaceuticals).
    Siegmund B, Zeitz M.
    IDrugs; 2003 Feb 11; 6(2):154-8. PubMed ID: 12789619
    [Abstract] [Full Text] [Related]

  • 18. Ischemic stroke with cardiac involvement in aortic thromboembolism.
    Colombo GM, Albi F, Salvini P, Sacco T, Cicchinelli M.
    Minerva Cardioangiol; 2006 Dec 11; 54(6):779-81. PubMed ID: 17167390
    [Abstract] [Full Text] [Related]

  • 19. Proteasome inhibition arrests neurite outgrowth and causes "dying-back" degeneration in primary culture.
    Laser H, Mack TG, Wagner D, Coleman MP.
    J Neurosci Res; 2003 Dec 15; 74(6):906-16. PubMed ID: 14648596
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.